Investing
AbbVie trims full-year profit forecast due to higher R&D expenses
© Reuters. Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
(Reuters) – AbbVie Inc (NYSE:) cut full-year profit forecast due to unfavorable impact from R&D and milestone expenses, the drugmaker said on Thursday.
The company now expects adjusted profit between $10.57 and $10.97 per share, compared with $10.72 to $11.12 per share it previously expected.
Read the full article here
-
Side Hustles6 days ago
Mark Zuckerberg Is Now Second Richest Person in the World
-
Investing6 days ago
Nvidia CEO Jensen Huang: Demand For Blackwell AI Is Insane
-
Side Hustles6 days ago
Meta Previews Movie Gen, AI Tools That Turn Dreams to Videos
-
Investing4 days ago
Hurricane Helene Hits Spruce Pine Mine, Quartz Used for Tech
-
Investing5 days ago
Israel stocks lower at close of trade; TA 35 down 0.23% By Investing.com
-
Investing6 days ago
BCA says investors should fade the real estate rally By Investing.com
-
Passive Income5 days ago
Go Paperless with the PDF Reader Pro for $49.99
-
Side Hustles5 days ago
5 Key Strategies for a Seamless Cloud Migration